Monitor the ASCO presentations in late May–early June 2026 for data quality and response rates, which could catalyze stock movement. Positive data may attract partnership interest, especially for IMA401 and the GEN2 platform.
IMTX drugs
IMTX drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 21 $11.18entry
- T+1 · 7mo ago +0.72%α −0.30% · $11.26
- T+5 · 7mo ago +3.67%α +2.58% · $11.59
- T+20 · 6mo ago −5.01%α −9.92% · $10.62
- T+60 · 4mo ago −15.92%α −22.82% · $9.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Immatics announced that four abstracts from its clinical programs will be presented as oral presentations at the 2026 ASCO Annual Meeting, including Phase 1b data for anzu-cel in melanoma, updated data for IMA203CD8 in gynecologic cancers, and first-in-human results for IMA401. This confirms scientific validation and visibility for its PRAME and MAGEA4/8-targeted therapies.
Key Facts
- Four oral presentations accepted at ASCO 2026, a top oncology conference
- Data includes Phase 1b results for anzu-cel in advanced melanoma and uveal melanoma
- Updated Phase 1a/1b data for IMA203CD8 (GEN2) in gynecologic cancers
- Updated Phase 1 data for PRAME cell therapy in synovial sarcoma
- First-in-human results for IMA401, a MAGEA4/8 bispecific, across multiple solid tumors
Financial Impact
No direct financial impact disclosed; potential for increased investor and partnership interest due to high-profile data presentation
Risk Factors
- Clinical data remains preliminary and subject to verification
- No guarantee of regulatory or commercial success despite presentation acceptance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0000950103-26-005970 |
| Document: dp245406_6k.htm | 0000950103-26-005970 |
| Document: 0000950103-26-005970-index-headers.html | 0000950103-26-005970 |
| Document: 0000950103-26-005970-index.html | 0000950103-26-005970 |
| Document: 0000950103-26-005970.txt | 0000950103-26-005970 |
Track record
23 reports on IMTX
7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +22.12% at T+20 after the May 12, 2026 report. 8 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $6.24 Now $6.17 −1.12% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $6.55 Now $6.17 −5.73% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 5/10 No price data
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $6.42 Now $6.17 −3.89% settles Nov 17
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 24, 202624d ago Press Release Bullish 6/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 23, 202624d ago 6-K Bullish 7/10 Entry $7.31 to $7.20 Now $6.17 −15.60% ▼ −1.50% −0.95% vs SPY
- Aug 27, 202611w ago Insider Buy Bullish 6/10 Entry $9.45 to $9.56 Now $6.17 −34.71% ▲ +1.16% +1.05% vs SPY
- Aug 26, 202611w ago 6-K Bearish 6/10 Entry $9.36 to $9.46 Now $6.17 +34.08% ▼ −1.07% −0.80% vs SPY
- Aug 18, 202612w ago 6-K Neutral 6/10 Entry $9.09 to $9.24 Now $6.17 −32.12% ▲ +1.65% +1.85% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers